content_image/61589.jpg content_image/61594.jpg content_image/61590.jpg content_image/61588.jpg content_image/61597.jpg
## Targeting Multiple Cancer Antigens 

The majority of solid tumor cancers are known to express antigens targeted by Titan’s products. Since many tumors express more than one antigen, Titan’s monoclonal antibodies can also be given in combination against certain cancers. 

## Attacking the carcinoembryonic antigen 

CeaVac targets the carcinoembryonic antigen (CEA), which is present on a number of cancers, including colorectal, non-small cell lung, pan- creatic and gastric cancer. CeaVac, which has demonstrated strong immune responses in clinical studies in colorectal cancer patients, is currently under investigation in a controlled Phase III trial in advanced colorectal cancer. 

<img src='content_image/61589.jpg'>

*To be initiated 2H 2002 

## TriGem GLYPH<H23008> 

<img src='content_image/61594.jpg'>

## CeaVac GLYPH<H23006> 

<img src='content_image/61590.jpg'>

## Attacking the human milk fat globule antigen 

TriAb targets the human milk fat globule (HMFG) antigen, which is present on a number of tumor types including breast, colorectal, non-small cell lung, ovarian, and pancreatic cancer. TriAb is being tested in breast cancer and also in combination with CeaVac for col- orectal and non-small cell lung cancers. 

## Attacking the GD2 ganglioside antigen 

TriGem targets the GD2 ganglioside, a carbohydrate antigen that is present on a number of tumor types including melanoma, small cell lung cancer, neuroblastoma and sarcoma. TriGem is planned to be tested in combination with TriAb for small cell lung cancer. 

<img src='content_image/61588.jpg'>

<img src='content_image/61597.jpg'>

## TriAb GLYPH<H23006> 

